ATE539153T1 - Primaten t-lymphotrophische viren - Google Patents

Primaten t-lymphotrophische viren

Info

Publication number
ATE539153T1
ATE539153T1 AT09075152T AT09075152T ATE539153T1 AT E539153 T1 ATE539153 T1 AT E539153T1 AT 09075152 T AT09075152 T AT 09075152T AT 09075152 T AT09075152 T AT 09075152T AT E539153 T1 ATE539153 T1 AT E539153T1
Authority
AT
Austria
Prior art keywords
htlv
primate
htlvs
novel
variety
Prior art date
Application number
AT09075152T
Other languages
English (en)
Inventor
Donald Burke
William Switzer
Walid Heneine
Thomas Folks
Nathan Wolfe
Mpoudi Eitel
Original Assignee
Us Gov Health & Human Serv
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Univ Johns Hopkins filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE539153T1 publication Critical patent/ATE539153T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT09075152T 2005-02-21 2006-02-21 Primaten t-lymphotrophische viren ATE539153T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65448405P 2005-02-21 2005-02-21

Publications (1)

Publication Number Publication Date
ATE539153T1 true ATE539153T1 (de) 2012-01-15

Family

ID=36655074

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06735500T ATE427351T1 (de) 2005-02-21 2006-02-21 Primaten t-lymphotrophische viren
AT09075152T ATE539153T1 (de) 2005-02-21 2006-02-21 Primaten t-lymphotrophische viren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT06735500T ATE427351T1 (de) 2005-02-21 2006-02-21 Primaten t-lymphotrophische viren

Country Status (7)

Country Link
US (3) US7794998B2 (de)
EP (2) EP1880006B1 (de)
AT (2) ATE427351T1 (de)
AU (1) AU2006216838B8 (de)
CA (1) CA2598547C (de)
DE (1) DE602006006047D1 (de)
WO (1) WO2006091511A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2598547C (en) 2005-02-21 2016-01-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Primate t-lymphotropic viruses
WO2006133795A2 (en) * 2005-05-02 2006-12-21 Institut Pasteur A new human t-cell lymphotropic virus (htlv-3): nucleic acid and peptidic sequences thereof and method for detecting htlv-3
CA2688724C (en) 2007-05-21 2016-03-29 The Gov. Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Services Novel simian t-cell lymphotropic virus
US10928398B2 (en) * 2008-12-17 2021-02-23 Cornell University Method for double staining colocalized nuclear-markers in histological lymphoid or bone marrow tissue sample
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
SMT201800284T1 (it) 2011-06-10 2018-07-17 Univ Oregon Health & Science Glicoproteine cmv e vettori ricombinanti
WO2014081882A2 (en) * 2012-11-20 2014-05-30 The Trustees Of Columbia University In The City Of New York Systems and methods for analyzing coding sequences based on genetic distances

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406841B1 (en) 1993-07-01 2002-06-18 Abbott Laboratories Methods for the detection of HTLV-II antibodies employing novel HTLV-II NRA envelope peptides
CA2598547C (en) * 2005-02-21 2016-01-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Primate t-lymphotropic viruses

Also Published As

Publication number Publication date
CA2598547A1 (en) 2006-08-31
US9435000B2 (en) 2016-09-06
WO2006091511A8 (en) 2007-11-22
US20100317034A1 (en) 2010-12-16
AU2006216838B2 (en) 2011-04-21
EP2194127A1 (de) 2010-06-09
ATE427351T1 (de) 2009-04-15
EP2194127B1 (de) 2011-12-28
US20080292657A1 (en) 2008-11-27
AU2006216838B8 (en) 2011-05-12
AU2006216838A1 (en) 2006-08-31
US8541221B2 (en) 2013-09-24
US20140080121A1 (en) 2014-03-20
US7794998B2 (en) 2010-09-14
EP1880006A2 (de) 2008-01-23
WO2006091511A3 (en) 2006-12-28
EP1880006B1 (de) 2009-04-01
DE602006006047D1 (en) 2009-05-14
CA2598547C (en) 2016-01-19
WO2006091511A2 (en) 2006-08-31

Similar Documents

Publication Publication Date Title
Peterhans et al. Pestiviruses: how to outmaneuver your hosts
MA33642B1 (fr) Composés chimiques
ECSP044933A (es) Método y montaje para aumentar el volumen del cabello
BRPI0821110B8 (pt) anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
EA201070794A1 (ru) Рекомбинантные антигены rsv
UA94717C2 (ru) Модифицированный вирус гриппа, предназначенный для мониторинга и повышения эффективности вакцины
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
WO2016178876A3 (en) Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
DK1942108T3 (da) Forbindelse indeholdende basisk gruppe samt anvendelse deraf
BRPI0519135A2 (pt) macrolÍdeos
Krajaejun et al. Transcriptome analysis reveals pathogenicity and evolutionary history of the pathogenic oomycete Pythium insidiosum
ATE427351T1 (de) Primaten t-lymphotrophische viren
EA201500643A1 (ru) Парвовирус свиней 5а, способы применения и вакцина
WO2009005040A1 (ja) 緑膿菌の外膜タンパク質pa4710
WO2005051318A3 (en) Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
EA202091835A1 (ru) Замещенные циклоалкилом пиразолопиримидины, обладающие активностью против rsv
WO2005084315A3 (en) Pyranoindole derivatives and the use thereof for the treatment of hepatitis c virus infection or disease
DK1587828T3 (da) Defensivproteiner
WO2007036735A3 (en) Immunogenic agents againts burkholderia psudomallei and/or burkholderia mallei, comprising lipopolysaccharide, capsular polysaccharide and/or proteins from burkholderia psuedomallei
NO20063871L (no) Fremgangsmaer for indusering av autolyse i infeksiose bakteria
Mustafa et al. Pandemic SARS Coronavirus-2 infections in humans-COVID-19
EA201591095A1 (ru) Белок slurp-1 для применения в лечении глазных болезней
Kushawaha et al. Nipah virus and its outbreaks in tropical areas
Kalugina et al. Studying of efficiency" Duo Ekvalan" at helminthoses of horses
Berezenko et al. Selection of candidate strain for vaccine against bovine coronavirus production